相关实验视频

Updated: Jan 15, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

考虑到"低":关于重新定义乳腺癌中的HER2状态的讨论 (综述)

Alexandros Georgiou¹, Evangelia Anna Spiteri¹, Demetrios A Spandidos²

¹School of Medicine, University of Crete, 71003 Heraklion, Greece.

Molecular and clinical oncology

|October 15, 2025

概括

通过特定测试得分来定义的低HER2乳腺癌,代表了一个独特的亚组. 新型疗法显示出有效性,建议修订分类,以获得更好的患者结果.

科学领域:

在瘤学瘤学.
分子病理学分子病理学
翻译研究是翻译研究.

背景情况:

乳腺癌的分类依赖于人类表皮生长因子受体2 (HER2) 状态.
由于诊断的进步,HER2-低瘤 (IHC 1+或2+,ISH阴性) 越来越多地被识别.
这个子组可能具有独特的生物和临床特征.

研究的目的:

审查HER2-低乳腺癌的生物学,病理学和分子特征.
突出这一新兴分类的临床相关性和治疗影响.
讨论 HER2 低水平乳腺癌管理的潜在指导方针修订.

主要方法:

文献综述综合了关于HER2生物学和病理学的当前知识.
对HER2-低瘤的分子分析数据的分析.
评估临床试验数据,包括抗体与药物合物的疗效.

主要成果:

低HER2瘤表现出明显的转录和突变特征,特别是在激素受体阳性环境中.
临床试验表明,在HER2低的乳腺癌中,trastuzumab-deruxtecan等药物的有效性显著.
目前的HER2分层可能无法完全捕捉这个子组的治疗潜力.

结论:

承认HER2-low作为一个离散的分类对于完善患者分层至关重要.
优化对低HER2乳腺癌的治疗选择可以改善临床结果.
建议对指导方针进行修订,以在乳腺癌管理中纳入低HER2状态.

关键词:

在HER2-低的水平下.乳腺癌乳腺癌乳腺癌分子生物学分子生物学分子病理学分子病理学

更多相关视频

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...